Nakiwala Rehema, Dasgupta Noopur, Wilson Rebecca, Lutter Erika I, Bolliger Jeanne L
Department of Chemistry, 107 Physical Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Department of Microbiology and Molecular Genetics, 307 Life Sciences East, Oklahoma State University, Stillwater, OK 74078, USA.
Pharmaceuticals (Basel). 2025 Feb 12;18(2):249. doi: 10.3390/ph18020249.
: Fungal pathogens are increasingly developing concerning resistance against the currently available antifungal drugs, which creates a constant demand for new antifungal agents. : Here, we report the synthesis of C3,N4-substituted triazole derivatives containing a N4-(2-((4-methoxybenzyl)thio)phenyl) group. By selectively removing the 4-methoxybenzyl group, we were able to access the free thiol analogs which, under oxidative conditions, undergo a cyclization reaction yielding a C5-substituted benzo[4,5]thiazolo[2,3-][1,2,4]triazole. We were able to show a broad functional group tolerance for the preparation of the triazole derivatives, as well as the tricyclic heteroarenes prepared thereof. Mechanistic investigations suggest that the oxidative cyclization reaction proceeds via an ionic pathway involving a disulfide intermediate. Isolation of the disulfide intermediate and resubjecting it to the reaction conditions shows that the presence of acid significantly increases its rate of conversion to the corresponding benzo[4,5]thiazolo[2,3-][1,2,4]triazole. Antifungal testing of both the novel triazoles and the benzo[4,5]thiazolo[2,3-][1,2,4]triazoles was carried out with (SC5314) and a clinical strain of (OK01). : Most of the novel sulfur-containing triazoles and benzo[4,5]thiazolo[2,3-][1,2,4]triazoles showed activity against (SC5314) and the emerging pathogen (OK01). : A series of new sulfur-containing triazoles and benzo[4,5]thiazolo[2,3-][1,2,4]triazoles were synthesized. Antifungal testing revealed modest activity against (SC5314) and (OK01).
真菌病原体对目前可用的抗真菌药物的耐药性日益增强,这使得对新型抗真菌药物的需求持续存在。在此,我们报告了含N4-(2-((4-甲氧基苄基)硫代)苯基)的C3,N4-取代三唑衍生物的合成。通过选择性地去除4-甲氧基苄基,我们能够得到游离硫醇类似物,在氧化条件下,这些类似物会发生环化反应生成C5-取代的苯并[4,5]噻唑并[2,3-][1,2,4]三唑。我们能够证明在制备三唑衍生物以及由此制备的三环杂芳烃时具有广泛的官能团耐受性。机理研究表明,氧化环化反应通过涉及二硫键中间体的离子途径进行。分离二硫键中间体并将其重新置于反应条件下表明,酸的存在显著提高了其转化为相应苯并[4,5]噻唑并[2,3-][1,2,4]三唑的转化率。对新型三唑和苯并[4,5]噻唑并[2,3-][1,2,4]三唑进行了抗真菌测试,测试对象为白色念珠菌(SC5314)和新型隐球菌临床菌株(OK01)。大多数新型含硫三唑和苯并[4,5]噻唑并[2,3-][1,2,4]三唑对白色念珠菌(SC5314)和新出现的病原体新型隐球菌(OK01)表现出活性。合成了一系列新型含硫三唑和苯并[4,5]噻唑并[2,3-][1,2,4]三唑。抗真菌测试显示对白色念珠菌(SC5314)和新型隐球菌(OK01)有适度活性。